Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Aringer, M; Houssiau, F; Gordon, C; Graninger, WB; Voll, RE; Rath, E; Steiner, G; Smolen, JS.
Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
Rheumatology (Oxford). 2009; 48(11):1451-1454
Doi: 10.1093/rheumatology/kep270
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Graninger Winfried
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- To follow-up on all available infliximab-treated SLE patients for safety and long-term efficacy in order to extract information that is useful for planning appropriate controlled trials with infliximab in SLE. We analysed charts of six patients treated in an open-label safety trial and seven additional patients treated with infliximab on a compassionate care basis for uncontrolled SLE organ inflammation. Out of nine patients with lupus nephritis, six had a long-term response after four infusions of infliximab in combination with AZA, lasting for up to 5 years. All five patients with lupus arthritis responded, but this response did not last for >2 months after the last infusion. One additional patient had a long-lasting improvement in SLE interstitial lung disease. No symptoms suggestive of infliximab-induced SLE flares occurred in any patients. Short-term treatment appeared relatively safe, but one patient developed deep-vein thrombosis and several infections. Under long-term therapy, two patients had life-threatening or fatal events, namely CNS lymphoma and Legionella pneumonia. Retreatment and treatment without concomitant immunosuppression led to drug reactions. Short-term therapy with four infusions of infliximab in combination with AZA was relatively safe, and had remarkable long-term efficacy for lupus nephritis and, potentially, also interstitial lung disease. Long-term therapy with infliximab, however, was associated with severe adverse events in two out of three SLE patients, which may have been provoked by infliximab and/or by their long-standing refractory SLE and previous therapies.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use
- Antirheumatic Agents - adverse effects Antirheumatic Agents - therapeutic use
- Azathioprine - adverse effects Azathioprine - therapeutic use
- Drug Administration Schedule -
- Drug Therapy, Combination -
- Female -
- Follow-Up Studies -
- Humans -
- Immunosuppressive Agents - adverse effects Immunosuppressive Agents - therapeutic use
- Infliximab -
- Lung Diseases, Interstitial - drug therapy
- Lupus Erythematosus, Systemic - drug therapy
- Lupus Nephritis - drug therapy
- Male -
- Middle Aged -
- Treatment Outcome -
- Tumor Necrosis Factor-alpha - antagonists & inhibitors
- Find related publications in this database (Keywords)
- Systemic lupus erythematosus
- Lupus nephritis
- Tumor necrosis factor-alpha
- Infliximab
- Safety